Scancell Holdings PLC's (LON:SCLP) Dr Cliff Holloway presents at the Proactive One2One Virtual Conference. The company's lead drug, SCIB-1, developed from its ImmunoBody technology, has recently entered a phase II clinical trial in the UK. The study will initially assess the safety and efficacy of the treatment in 25 people with a metastatic form of skin cancer, melanoma. SCIB-1 will be used in harness with Merck’s checkpoint inhibitor Keytruda.
29 Aug 20